Compounds > etisulergine
Page last updated: 2024-11-06

etisulergine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

etisulergine: RN given refers to parent cpd; CQ 32084 is synonomous to HCl; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68847
CHEMBL ID38992
SCHEMBL ID219311
MeSH IDM0099256

Synonyms (18)

Synonym
etisulergine
CHEMBL38992
etisulergina [inn-spanish]
64795-23-9
n,n-diethyl-n'-(6-methylergolin-8alpha-yl)sulfamide
unii-28n73q6o7y
etisulerginum
cq 32-084
etisulerginum [inn-latin]
etisulergina
28n73q6o7y ,
etisulergine [inn]
SCHEMBL219311
n,n-diethyl-n'-(6-methylergolin-8.alpha.-yl)sulfamide
bdbm50225361
Q27254335
(6ar,9s,10ar)-9-(diethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline
DTXSID101024323
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (20)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00040.629810.0000AID203936; AID203937
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)5.00000.00040.908610.0000AID203936; AID203937
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.30000.00021.874210.0000AID32964
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)5.00000.00031.38338.4000AID203936; AID203937
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)0.08200.00100.79948.0000AID62437; AID62438; AID62441; AID62442
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.30000.00021.270410.0000AID32964
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00051.48357.8000AID203936; AID203937
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00311.73607.8000AID203936; AID203937
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.79627.8000AID203936; AID203937
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00040.615610.0000AID203936; AID203937
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.50894.6000AID203936; AID203937
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.42824.6000AID203936; AID203937
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.35984.6000AID203936; AID203937
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.35984.6000AID203936; AID203937
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)5.00000.00021.13514.6000AID203936; AID203937
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.30000.00001.819410.0000AID32964
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.35524.6000AID203936; AID203937
DBos taurus (cattle)IC50 (µMol)0.08200.00100.47208.0000AID62437; AID62438; AID62441; AID62442
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)5.00000.00030.70285.3660AID203936
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00041.17424.6000AID203936; AID203937
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID62310Dopamine receptor binding affinity by displacing the radioligand [3H]-dopamine from dopamine receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID203935In vitro inhibitory activity against serotonin receptor from rat frontal cortex using [3H]spiperone as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID62430Dopamine receptor binding affinity by displacing the radioligand [3H]spiroperidol from dopamine receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID182642Compound was evaluated for the in vivo inhibition of basal prolactin for a time 4 hr after injection in male rats1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID62438In vitro inhibitory activity against dopamine receptor from calf caudate using [3H]spiperone as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID32964In vitro inhibitory activity was evaluated against,[3H]WB 4101 whole rat brain alpha 1-adrenoceptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID36920In vitro inhibitory activity was evaluated against,[3H]clonidine (Clon) rat brain minus cerebellum Alpha-2 adrenergic receptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID191322Compound was evaluated for the contralateral turning in 6-hydroxy-dopamine-lesioned rats administered intraperitoneally at the dose 1 mg/kg1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID203936In vitro inhibitory activity against serotonin receptor from whole rat brain using [3H]5-HT as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID174604Compound was evaluated for the contralateral turning in 6-hydroxy-dopamine-lesioned rats administered intraperitoneally at the dose 1 mg/kg1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID62442In vitro inhibitory activity was evaluated against,[3H]spiperone calf caudate (SPC) dopamine receptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID182951In vivo inhibitory activity against ovum implantation in female rat after subcutaneous administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID182949In vivo inhibitory activity against basal prolactin in male rat after subcutaneous administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID62441In vitro inhibitory activity was evaluated against,[3H]dopamine (DA),calf caudate dopamine receptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID203938In vitro inhibitory activity was evaluated against,[3H]spiperone rat frontal cortex (SPFC) serotonin receptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID203937In vitro inhibitory activity was evaluated against,[3H]serotonin (5-HT) whole rat brain serotonin receptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
AID36861In vitro inhibitory activity against alpha-1 adrenergic receptor from whole rat brain using [3H]WB-4101 as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID185915Compound was evaluated for the contralateral turning in 6-hydroxy-dopamine-lesioned rats administered intraperitoneally at the dose 1 mg/kg1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID182954In vivo inhibitory against lactation in female rat after peroral administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID62437In vitro inhibitory activity against dopamine receptor from calf caudate using [3H]dopamine as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID36919In vitro inhibitory activity against alpha-2 adrenergic receptor from rat brain minus cerebellum using [3H]clonidine as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (86.67)18.7374
1990's2 (13.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin
2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin: potent, specific D2 dopamine receptor agonist; RN given refers to parent cpd		1.9610tetralins
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		1.9610benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		1.9610dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		1.9610aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		1.9610aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		1.9810benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		2.6530aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		2.3720amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		1.9610methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
lisuride
Lisuride: An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS).		2.8840monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
n-n-propylnorapomorphine
N-n-propylnorapomorphine: RN given refers to cpd without isomeric designation; structure		1.9610
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		3.2160indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
pergolide
Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		2.8840diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
quinpirole
Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.		1.9610pyrazoloquinolinedopamine agonist
mesulergine
mesulergine: RN given refers to parent cpd; CU 32-085 is synonymous to mono-HCl; metabolized into dopaminergic agonists; structure given in first source. mesulergine : A member of the class of ergot alkaloids that is known to act on serotonin and dopamine receptors.		4.4551ergot alkaloid;
sulfamides		antiparkinson drug;
dopamine agonist;
serotonergic antagonist
5-hydroxy-2-n,n-dipropylaminotetralin
5-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation		1.9610
dironyl
dironyl: pronounced antifertility agent in rats; lactation suppressor in other species; serotonin antagonist; RN given refers to parent cpd; structure		1.9710organic molecular entity
quinagolide
quinagolide: structure & RN given in first source; a non-ergot dopamine D(2)-agonist		2.3720organic heterotricyclic compound;
organonitrogen heterocyclic compound
preclamol
preclamol: centrally acting dopamine receptor agonist with selectivity for autoreceptors		1.9710
ergoline
Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.		5.22121diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound
cqp 201-403
CQP 201-403: belongs to class of 8-aminoergolines		1.9810
piperidines
Piperidines: A family of hexahydropyridines.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610
Idiopathic Parkinson Disease
[description not available]		04.0431
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		04.0431
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		01.9610